Back to top
more

Baxter International (BAX)

(Real Time Quote from BATS)

$22.60 USD

22.60
4,364,636

-0.24 (-1.05%)

Updated Aug 6, 2025 02:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (148 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.

Zacks Equity Research

Is the Options Market Predicting a Spike in Baxter International (BAX) Stock?

by Zacks Equity Research

Investors need to pay close attention to Baxter International (BAX) stock based on the movements in the options market lately.

Zacks Equity Research

New Strong Sell Stocks for November 29th

by Zacks Equity Research

BALY, BAX and CENTA have been added to the Zacks Rank #5 (Strong Sell) List on November 29, 2024.

Zacks Equity Research

New Strong Sell Stocks for November 21st

by Zacks Equity Research

BATRA, BAX and BRKR have been added to the Zacks Rank #5 (Strong Sell) List on November 21, 2024.

Zacks Equity Research

BAX Stock Falls Despite Q3 Earnings & Sales Beat, Margins Decline

by Zacks Equity Research

Baxter reports better-than-expected third-quarter results. However, the company's gross and operating margins contract. Shares fall.

Zacks Equity Research

Baxter (BAX) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

Although the revenue and EPS for Baxter (BAX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Baxter International (BAX) Beats Q3 Earnings Estimates

by Zacks Equity Research

Baxter (BAX) delivered earnings and revenue surprises of 2.56% and 29.72%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Haemonetics (HAE) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Haemonetics (HAE) delivered earnings and revenue surprises of 2.75% and 0.73%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Strong Demand and Positive Pricing to Drive Baxter's Q3 Earnings

by Zacks Equity Research

BAX's third-quarter results are likely to benefit from a positive pricing impact and new product launches. However, supply-chain issues are likely to have raised expenses in the quarter.

Zacks Equity Research

Countdown to Baxter (BAX) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS

by Zacks Equity Research

Evaluate the expected performance of Baxter (BAX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks Equity Research

Here's Why You Should Retain ABT Stock in Your Portfolio Now

by Zacks Equity Research

Investors feel optimistic about Abbott's robust strength in the Diagnostics and Nutrition business. Yet, unfavorable forex impacts are concerning.

Zacks Equity Research

BSX Q3 Earnings Top, Stock Down in Premarket as Operating Margin Falls

by Zacks Equity Research

Boston Scientific registers year-over-year improvement in sales, indicating solid market share gains in legacy businesses despite macroeconomic odds.

Zacks Equity Research

Growing Biosimilars Business Supports ABT Stock, Macro Issues Hurt

by Zacks Equity Research

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

Zacks Equity Research

Is Insulet Stock a Smart Addition to Your Portfolio Right Now?

by Zacks Equity Research

PODD continues to make strides with Omnipod 5 and its market expansion. Robust solvency is a plus.

Zacks Equity Research

Cencora Rallies 14.7% Year to Date: What's Driving the Stock?

by Zacks Equity Research

COR is gaining traction from the robust U.S. Healthcare Solutions segment, which raises optimism about the stock.

Zacks Equity Research

BAX or LMAT: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

BAX vs. LMAT: Which Stock Is the Better Value Option?

Zacks Equity Research

Should Value Investors Buy Baxter International (BAX) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks Equity Research

GKOS Stock Rises on Positive Phase 3 Confirmatory Trial for Epioxa

by Zacks Equity Research

Glaukos announces positive second Phase 3 confirmatory pivotal trial for Epioxa.

Zacks Equity Research

Here's Why You Should Retain Accuray Stock in Your Portfolio Now

by Zacks Equity Research

ARAY's solid product demand and revenue growth raise optimism about the stock.

Zacks Equity Research

Catalent Stock Flat Following the Sell Agreement With Ardena

by Zacks Equity Research

CTLT announces an agreement to sell its oral solids development and manufacturing facility in Somerset to Ardena.

Zacks Equity Research

HealthEquity Gains 28.3% YTD: What's Driving the Stock?

by Zacks Equity Research

HQY's sustained strength in HSAs raises optimism about the stock.

Zacks Equity Research

Reasons to Retain PacBio Stock in Your Portfolio for Now

by Zacks Equity Research

PACB's strong product demand and continued focus on R&D raise optimism about the stock.

Zacks Equity Research

SNN Stock May Gain Following the Co-Marketing Deal With JointVue

by Zacks Equity Research

Smith & Nephew and JointVue announce a co-marketing agreement for the latter's OrthoSonic 3D Surgery Planning Technology.

Zacks Equity Research

BDX Stock Up on Robotics Solution Launch to Boost Single-Cell Research

by Zacks Equity Research

BD aims to automate the complex library preparation process to aid researchers get consistent results and minimize the variability stemming from manual procedures.

Zacks Equity Research

SIBN Stock Up After First-In-Patient Use of FDA Breakthrough Device

by Zacks Equity Research

SI-BONE aims to address the unmet clinical needs of complex pelvic fragility fractures by providing a solution that improves both surgical efficiency and patient recovery.

Zacks Equity Research

Here's Why You Should Retain Glaukos Stock in Your Portfolio Now

by Zacks Equity Research

GKOS continues to benefit from a robust demand for its products and expansion in new markets. A strong development pipeline raises optimism.